Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02823145
Registration number
NCT02823145
Ethics application status
Date submitted
13/06/2016
Date registered
6/07/2016
Date last updated
25/09/2023
Titles & IDs
Public title
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome
Query!
Scientific title
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome
Query!
Secondary ID [1]
0
0
2016-002804-14
Query!
Secondary ID [2]
0
0
ZX008-1503
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Dravet Syndrome
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Epilepsy
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ZX008 (Fenfluramine Hydrochloride)
Experimental: ZX008 - ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
Treatment: Drugs: ZX008 (Fenfluramine Hydrochloride)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period
Query!
Assessment method [1]
0
0
Treatment-emergent adverse events (TEAE) were defined as any AEs that based on start date information occurs after the first intake of study treatment.
Query!
Timepoint [1]
0
0
From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)
Query!
Primary outcome [2]
0
0
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the OLE Treatment Period
Query!
Assessment method [2]
0
0
A TEAE was defined as any AE that based on start date information occurs after the first intake of study treatment. Percentage of participants with TEAEs leading to withdrawal from IMP during OLE Treatment Period were reported.
Query!
Timepoint [2]
0
0
From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)
Query!
Primary outcome [3]
0
0
Percentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the OLE Treatment Period
Query!
Assessment method [3]
0
0
Serious Adverse event (SAE) was defined as any untoward medical occurrence that at any dose: • results in death, • is life-threatening threatening, • results in initial inpatient hospitalization or prolongation of hospitalization, •results in persistent or significant disability or incapacity, • results in a congenital anomaly/birth defect, • results in any medically significant event that did not meet any of the other 5 SAE criteria, but which was judged by a physician to potentially jeopardize the participant or require medical or surgical intervention to prevent one of the above outcomes listed as an SAE criterion.
Query!
Timepoint [3]
0
0
From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)
Query!
Secondary outcome [1]
0
0
Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Day 1 to End of Study (EOS) Visit (Month 42) in the OLE Treatment Period
Query!
Assessment method [1]
0
0
Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies (ZX008-1501/ZX008-1502, and ZX008-1504 Cohort 2). Participants in 1504- Cohort 1 and de novo participants (who entered 1503 without having been in any of the core studies) did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Day 1 to EOS was divided by the total number of days from Day 1 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day convulsive seizure frequency (CSF). The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.
Query!
Timepoint [1]
0
0
From Day 1 to End of OLE Treatment Period (EOS Visit - up to Month 42), compared to Baseline (Core)
Query!
Secondary outcome [2]
0
0
Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Month 2 to EOS (Month 42) in the OLE Treatment Period
Query!
Assessment method [2]
0
0
Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies. Participants in 1504-Cohort 1 and de novo participants did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Month 2 to EOS was divided by the total number of days from Month 2 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF. The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.
Query!
Timepoint [2]
0
0
From Month 2 to End of OLE Treatment Period (EOS Visit - up to Month 42), compared to Baseline (Core)
Query!
Secondary outcome [3]
0
0
Convulsive Seizure Frequency (CSF) Per 28 Days During the OLE Treatment Period (to Month 36)
Query!
Assessment method [3]
0
0
Monthly (28 day) CSF was based on electronic diary data obtained for each participant. The total number of convulsive seizures in the ith interval (CSF in OLE, where, i=1, 2, 3, … , 14 ) was divided by the total number of days in the ith interval with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF of OLE.
Query!
Timepoint [3]
0
0
At Month 1, Month 2, Month 3, Month 4-6, Month 7-9, Month 10-12, Month 13-15, Month 16-18, Month 19-21, Month 22-24, Month 25-27, Month 28-30, Month 31-33, and Month 34-36
Query!
Secondary outcome [4]
0
0
Convulsive Seizure Frequency (CSF) by Mean Daily Dose During the Overall OLE Treatment Period
Query!
Assessment method [4]
0
0
Convulsive seizure frequency over time, reported as per 28 days was analyzed by the actual dose administered. Participants were grouped into low (0.2 to <0.4 mg/kg), medium (0.4 to <0.6 mg/kg), and high dose (>0.6 mg/kg) groups depending on their mean daily doses of ZX008 during the OLE Treatment period. For each participant, the seizure frequency per 28 days was calculated as the number of seizures recorded during the period, divided by the number of days in the period and multiplied by 28. The convulsive seizure frequency was calculated from all available data collected.
Query!
Timepoint [4]
0
0
From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Changes in Antiepileptic Drug (AED) Medications During First 6 Months of OLE Treatment Period
Query!
Assessment method [5]
0
0
Participants in the study were required to be on stable background therapy for the first 6 months of treatment, after which background AEDs could be reduced or withdrawn so long as one background AED remained. The percentage of participants who had changes in dose or type of concomitant AED medications during the first, second, third, fourth, fifth, and sixth months were analyzed and reported.
Query!
Timepoint [5]
0
0
At Month 1, 2, 3, 4 , 5, and 6 of OLE Treatment Period
Query!
Eligibility
Key inclusion criteria
Key
- Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day
of the core study Screening Visit.
- Satisfactory completion of the core study in the opinion of the investigator and the
sponsor.
- Subjects who are >18 to =35 years of age at the time of screening and did not
participate in one of the core studies may be eligible for participation.
- A documented medical history to support a clinical diagnosis of Dravet syndrome, where
convulsive seizures are not completely controlled by current antiepileptic drugs.
- Parent/caregiver is willing and able to be compliant with diary completion, visit
schedule and study drug accountability.
- Subject's parent/caregiver has been compliant with diary completion during the core
study, in the opinion of the investigator (eg, at least 90% compliant).
Key
Query!
Minimum age
2
Years
Query!
Query!
Maximum age
35
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Current or past history of cardiovascular or cerebrovascular disease, myocardial
infarction or stroke.
- Current cardiac valvulopathy or pulmonary hypertension that is clinically significant
and warrants discontinuation of study medication.
- Current or past history of glaucoma.
- Moderate or severe hepatic impairment.
- Receiving concomitant therapy with: centrally-acting anorectic agents;
monoamineoxidase inhibitors; any centrally-acting compound with clinically appreciable
amount of serotonin agonist or antagonist properties, including serotonin reuptake
inhibition; atomoxetine, or other centrally-acting noradrenergic agonist;
cyproheptadine, and/or cytochrome P450 (CYP) 2D6/3A4/2B6 inhibitors/substrates.
- Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or
phenytoin, or has taken any of these within the past 30 days, as maintenance therapy.
- A clinically significant condition, or has had clinically relevant symptoms or a
clinically significant illness at Visit 1, other than epilepsy, that would negatively
impact study participation, collection of study data, or pose a risk to the subject.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/06/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/01/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
375
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Melbourne Brain Centre Austin Hospital - Heidelberg
Query!
Recruitment hospital [2]
0
0
Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital - South Brisbane
Query!
Recruitment hospital [3]
0
0
The Children's Hospital Westmead Dept. of Neurology and Neurosurgery - Westmead
Query!
Recruitment postcode(s) [1]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [2]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
- Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Minnesota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Utah
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Washington
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Edegem
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Montréal
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Vancouver
Query!
Country [20]
0
0
Denmark
Query!
State/province [20]
0
0
Dianalund
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Amiens
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Bordeaux
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Lille
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Marseille
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Berlin
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Bielefeld
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Freiburg
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Jena
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Kiel
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Radeberg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Tübingen
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Vogtareuth
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Firenze
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Genova
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Mantova
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Milano
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Roma
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Verona
Query!
Country [40]
0
0
Japan
Query!
State/province [40]
0
0
Saitama
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Shizuoka
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Tokyo
Query!
Country [43]
0
0
Netherlands
Query!
State/province [43]
0
0
Heeze
Query!
Country [44]
0
0
Netherlands
Query!
State/province [44]
0
0
Zwolle
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Barcelona
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Madrid
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Pamplona
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
Birmingham
Query!
Country [49]
0
0
United Kingdom
Query!
State/province [49]
0
0
Glasgow
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Liverpool
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
London
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an international, multicenter, open-label, long-term safety study of ZX008 in
subjects with Dravet syndrome.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02823145
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
UCB Cares
Query!
Address
0
0
001 844 599 2273
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02823145
Download to PDF